Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 348,800 shares, a decline of 24.5% from the February 13th total of 462,200 shares. Based on an average daily trading volume, of 232,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.4% of the company’s stock are sold short.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sprott Inc. acquired a new stake in Gain Therapeutics during the fourth quarter worth about $30,000. Benedict Financial Advisors Inc. acquired a new stake in Gain Therapeutics during the fourth quarter worth about $35,000. Bridgeway Capital Management LLC acquired a new stake in Gain Therapeutics during the fourth quarter worth about $65,000. Northern Trust Corp raised its stake in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after acquiring an additional 39,642 shares during the period. Finally, Jones Financial Companies Lllp raised its stake in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after acquiring an additional 44,750 shares during the period. Institutional investors and hedge funds own 11.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research report on Monday. Roth Mkm reissued a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Finally, Scotiabank assumed coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Down 0.8 %

Shares of GANX traded down $0.02 during midday trading on Tuesday, hitting $2.38. The company had a trading volume of 193,593 shares, compared to its average volume of 278,390. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.63. The company’s 50 day moving average price is $2.23 and its 200 day moving average price is $2.01. The stock has a market cap of $63.13 million, a price-to-earnings ratio of -2.16 and a beta of 0.14.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.